Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News EOM Pharmaceutical Holdings Inc IMUC

Healthcare Biotechnology
EOM Pharmaceutical Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing novel drugs for patients suffering from debilitating and deadly diseases, including infectious diseases; autoimmune diseases including rheumatoid arthritis; and cachexia associated with acquired immune deficiency syndrome (AIDS) and cancer. It has two pipeline assets in their... see more

Recent & Breaking News (PINL:IMUC)

ImmunoCellular Therapeutics to Report Third Quarter 2015 Financial Results on November 10, 2015

PR Newswire October 27, 2015

ImmunoCellular Therapeutics Awarded $19.9 Million Grant from California Institute for Regenerative Medicine (CIRM) to Fund ICT-107 Phase 3 Registration Program in Glioblastoma

PR Newswire September 24, 2015

ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors

PR Newswire September 22, 2015

ImmunoCellular Therapeutics Issues Letter to Shareholders, Highlighting Progress on Advancing ICT-107 to Phase 3 Registrational Trial

PR Newswire August 21, 2015

ImmunoCellular Therapeutics Reaches Agreement with FDA on Special Protocol Assessment (SPA) for ICT-107 Phase 3 Registrational Trial in Glioblastoma

PR Newswire August 13, 2015

ImmunoCellular Therapeutics Announces Second Quarter 2015 Financial Results

PR Newswire August 6, 2015

ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015

PR Newswire July 23, 2015

ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma

PR Newswire July 6, 2015

ImmunoCellular Therapeutics to Present at Cantor Fitsgerald Inaugural Healthcare Conference on July 8th

PR Newswire June 29, 2015

ImmunoCellular Therapeutics Establishes Agreement with Pure MHC for Novel Quality Control Assay for ICT-107 Phase 3 Registrational Trial

PR Newswire June 22, 2015

PCT, a Caladrius Company, Expands Relationship With ImmunoCellular Therapeutics to Provide Manufacturing For Their Phase 3 Trial

GlobeNewswire June 15, 2015

ImmunoCellular Therapeutics Enters into Manufacturing Agreement with PCT LLC, a Caladrius Company, for US Production of ICT-107 for Phase 3 Registration Trial

PR Newswire June 15, 2015

ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on May 28th

PR Newswire May 19, 2015

ImmunoCellular Therapeutics Announces First Quarter 2015 Financial Results

PR Newswire May 11, 2015

ImmunoCellular Therapeutics Presentation Now Available for On-Demand Viewing

PR Newswire May 11, 2015

ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7

PR Newswire May 5, 2015

NYSE, Nasdaq and OTC Markets Companies to Present, Online, to Investors on May 7

Canada NewsWire May 4, 2015

ImmunoCellular Therapeutics to Report First Quarter 2015 Financial Results on May 11, 2015; Conference Call and Webcast to be Held on May 12, 2015

PR Newswire April 30, 2015

ImmunoCellular Therapeutics Establishes Manufacturing Agreement with PharmaCell B.V. for European Production of ICT-107 for Phase 3 Registration Trial

PR Newswire March 19, 2015

ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results

PR Newswire March 9, 2015